COVID‐19 in three people living with HIV in the United Kingdom

Toombs, Jessica M.; Abbeele, Koenraad Van den; Democratis, Jane; Merricks, Rhona; Mandal, Amit K J; Missouris, Constantinos G

doi:10.1002/jmv.26178

Cited by 24 publications

(26 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical course and outcome of COVID-19 among patients with HIV-1 infection are still unknown. Some authors have speculated that HIV-1-infected patients on cART may have a lower risk for COVID-19 and related complications because of the in vitro activity of some antiretroviral drugs against SARS-CoV-2 and their defective cellular immunity, leading to a decreased possibility of cytokine dysregulation and consequent severe lung damage [ 12 , 13 ]. On the contrary, other authors have suggested an increased risk for COVID-19 due to HIV-1-related immunosuppression [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy

et al. 2020

View full text Add to dashboard Cite

Background Since the end of February 2020, the Coronavirus Disease 2019 (COVID-19) outbreak rapidly spread throughout Italy and other European countries, but limited information has been available about its characteristics in HIV-infected patients. Methods We have described a case series of patients with HIV infection and COVID-19 diagnosed at the S.Orsola Hospital (Bologna, Italy) during March and April, 2020. Results We reported a case series of 26 HIV-infected patients with COVID-19. Nineteen subjects were men, the median age was 54 years, 73% of patients had one or more comorbidities. Only 5 patients with interstitial pneumonia were hospitalized, but there were no admissions to intensive care unit and no deaths. Conclusions In our experience, COVID-19 associated with HIV infection had a clinical presentation comparable to the general population and was frequently associated with chronic comorbidities.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…To the Editor, Toombs et al provide an important contribution to the emerging literature which seeks to establish if those people living with human immunodeficiency virus (PLWH) are disproportionately affected by the coronavirus disease 2019 (COVID-19) pandemic. 1 Evidence from their case series have been consistent with the hypothesis that PLWH do not experience disproportionately greater hospital admission, morbidity, or mortality.…”

Section: E T T E R T O T H E E D I T O R Covid-19 and Hiv Co-infectmentioning

confidence: 61%

COVID‐19 and HIV co‐infection an emerging consensus

Masukume

Mapanga

Grinberg

et al. 2020

Journal of Medical Virology

View full text Add to dashboard Cite

“…During the last decades, the design of new oxadiazole-based scaffolds accelerated in medicinal chemistry, bringing most of these compounds to the preclinical stage or, even, to commercialization. Among these, the most commercially available drugs are Oxolamine, a cough suppressant [ 16 ], Ataluren, indicated for the treatment of Duchenne muscular dystrophy [ 17 ] and cystic fibrosis [ 18 ], Butalamine, a vasodilator, Proxazole, a drug for functional gastrointestinal disorders, Fasiplon, an anxiolytic drug [ 19 ], Raltegravir, an antiretroviral drug used to treat HIV [ 20 ], which has been recently proposed as repurposing drug against SARS-COV-2 [ 21 ], as well as the antiviral Pleconaril selected for the SARS-COV-2 spike protein [ 22 ] ( Figure 2 ). Equally well known is Zibotentan, an anticancer drug in late-stage clinical trials ( Identifier: NCT00554229), which is a candidate in development by AstraZeneca ( Figure 2 ).…”

Section: Introductionmentioning

confidence: 99%

Groundbreaking Anticancer Activity of Highly Diversified Oxadiazole Scaffolds

Benassi

Doria

Pirota

2020

IJMS

View full text Add to dashboard Cite

Nowadays, an increasing number of heterocyclic-based drugs found application in medicinal chemistry and, in particular, as anticancer agents. In this context, oxadiazoles—five-membered aromatic rings—emerged for their interesting biological properties. Modification of oxadiazole scaffolds represents a valid strategy to increase their anticancer activity, especially on 1,2,4 and 1,3,4 regioisomers. In the last years, an increasing number of oxadiazole derivatives, with remarkable cytotoxicity for several tumor lines, were identified. Structural modifications, that ensure higher cytotoxicity towards malignant cells, represent a solid starting point in the development of novel oxadiazole-based drugs. To increase the specificity of this strategy, outstanding oxadiazole scaffolds have been designed to selectively interact with biological targets, including enzymes, globular proteins, and nucleic acids, showing more promising antitumor effects. In the present work, we aim to provide a comprehensive overview of the anticancer activity of these heterocycles, describing their effect on different targets and highlighting how their structural versatility has been exploited to modulate their biological properties.

show abstract

COVID‐19 in three people living with HIV in the United Kingdom

Cited by 24 publications

References 7 publications

COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy

COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy

COVID‐19 and HIV co‐infection an emerging consensus

Groundbreaking Anticancer Activity of Highly Diversified Oxadiazole Scaffolds

Contact Info

Product

Resources

About